PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29928488-3	2018	We have found that ruxolitinib downregulated the mTORC1/S6K/4EBP1 pathway at least partly through inhibition of the STAT5/Pim-2 pathway with concomitant downregulation of c-Myc, MCL-1, and BCL-xL as well as induction of autophagy in these cells.	ruxolitinib	19-30	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	171-176	
35269680-5	2022	Furthermore, in the MDA-MB-468 xenograft mouse model, we demonstrated the synergistic antitumor effect of ruxolitinib and calcitriol combination treatment, including the alteration of c-PARP, cyclin D1, and c-Myc expression, without significant drug toxicity.	ruxolitinib	106-117	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	207-212	
27668411-7	2017	Furthermore, treatment of stimulated MYC deprived cells with MLN120b, ACHP, Pyridone 6 or Ruxolitinib showed that IL10/CpG induced proliferation and CDK4 expression were JAK/STAT3 and IKK/NF-kappaB dependent.	ruxolitinib	90-101	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	37-40	
26811457-5	2016	In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2.	ruxolitinib	42-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	115-120